Cadre price to free cash flow CDRE

Market value divided by free cash flow over the last twelve months, since 2022.

Today, Oct 23, 2026: 16.4×
4-year median: 24.6×
Against its 4-year history: 3rd; percentile: 0 is its lowest day, 100 its highest
4-year range: 13.5× to 57.0×
Peer median: 26.2×

Cadre's price to free cash flow is 16.4× as of Oct 23, 2026.

That is below its 4-year median of 24.6×, lower than on 97% of days in the last 4 years.

Over that time it ranged from 13.5× in Oct 2026 to 57.0× in Jan 2025.

The median for 10 medical instruments and supplies stocks of a similar size is 26.2×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	16.4×	13.5×	29.4×
2025	27.8×	26.7×	57.0×
2024	46.2×	18.6×	51.2×
2023	21.6×	16.4×	25.3×
2022	21.4×	21.4×	34.3×

Against its peers

Companies in Medical - Instruments & Supplies nearest Cadre's size, closest first, today.

Company	Price to free cash flow
CDRECadre	16.4×
BVSBioventus	13.3×
STAAStaar Surgical	n/m
EYENational Vision	30.1×
IRMDIradimed	43.7×
LMATLemaitre Vascular	26.2×
INSPInspire Medical Systems	17.6×
UFPTUFP Technologies	n/m
MOVMovado	9.8×
MDXGMimedx	n/m
ATRCAtriCure	56.5×
Peer median	26.2×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Cadre

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.